A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer.

ABSTRACT: The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease. The genetic alterations underlying this heterogeneity have been thoroughly characterized through omic approaches requiring elevated efforts and costs. In order to translate the knowledge of CRC molecular heterogeneity into a practical clinical approach, we utilized a simplified Next Generation Sequencing (NGS) based platform to screen a cohort of 77 patients treated with first-line conventional therapy. Samples were sequenced using a panel of hotspots and targeted regions of 22 genes commonly involved in CRC. This revealed 51 patients carrying actionable gene mutations, 22 of which carried druggable alterations. The

SUBMITTER: Capalbo C 

PROVIDER: S-EPMC6406354 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature